Infertility, Female Clinical Trial
Official title:
The Effect of Vaginal Sildenafil on the Outcome of IVF/ICSI Cycles in Patients With Repeated IVF/ICSI Failure: a Pilot Study
Adequate growth of the endometrium is crucial for implantation. Accordingly, the pregnancy success rate of patients with a thin endometrium is low. Furthermore, there is a little information about the factors responsible for impaired endometrial growth in patients with a thin endometrium. The researches have revealed that nitric oxide (NO) release can cause relaxation of vascular smooth muscle through a cyclic guanyl monophosphate (cGMP)-mediated pathway. Sildenafil is a type 5-specific Phosphodiesterase inhibitor that augments the vasodilatory effects of NO on vascular smooth muscle by preventing the degradation of cGMP and could improve blood flow and endometrial thickness. This study is designed to evaluate the effect of vaginally administered sildenafil suppositories on IVF/ICSI outcome of infertile patients with repeated IVF/ICSI failures.
The proposal of this study approved by our institutional review boards and institution's
ethical committee, and all participants will sign a written consent before enter to study.
The study population will consist of infertile women of <38 years of age with repeated in
vitro fertilization/ intra cytoplasmic injection failures. Endometrial parameters including
endometrial thickness, endometrial pattern , pulsatility index (PI) and resistance index
(RI) will be evaluated with the use of color Doppler ultrasound on the day of hCG
administration. Patients will be randomly divided into 3 groups, A, B and C. In the
subsequent menstrual cycle, in group A, vaginal sildenafil suppositories (100 mg/day) will
be given daily from the start of human menopausal gonadotropin (HMG) administration day
until the day of oocyte retrieval. In group B, the women will receive daily vaginal placebo
from the start of HMG administration day until 2 days before the human chronic gonadotrophin
(hCG) injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day)
until the day of oocyte retrieval. In group C, vaginal placebo will be given daily from the
start of human menopausal gonadotropin (HMG) administration day until the day of oocyte
retrieval.
When the diameter of at least 2 follicles will be reached equal or greater than 18 mm, hCG
10,000 IU will be administered. In all patients, ovarian stimulation will be performed with
the conventional GnRh agonist protocol. Endometrial parameters will be measured again on the
day of hCG injection. Ovum pick up will be performed 34-36 h after hCG injection and embryos
will be transferred 48-72 hours after oocyte retrieval. Pregnancy will be confirmed by
assessment of βHCG level 14 days after embryo transfer and ultrasonographic visualization of
gestational sac during the 5th week of pregnancy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05969574 -
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
|
||
Recruiting |
NCT05358483 -
PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Completed |
NCT03177538 -
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
|
Phase 4 | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Completed |
NCT04052464 -
The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
|
||
Withdrawn |
NCT04753736 -
Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC
|
N/A | |
Completed |
NCT03349905 -
Deferred Versus Fresh Embryo Transfers
|
N/A | |
Completed |
NCT05076981 -
Progesterone Levels During Ovulation and Luteal Phase
|
||
Completed |
NCT04096027 -
Cabergoline Before or After Oocyte Collection for Follicular Resolution
|
Phase 4 | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Terminated |
NCT01933633 -
Improved Fertility After Exercise in Overweight/Obese Women
|
N/A | |
Completed |
NCT01202656 -
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
|
Phase 1/Phase 2 | |
Terminated |
NCT01202643 -
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
|
Phase 1/Phase 2 | |
Completed |
NCT01408615 -
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
|
||
Enrolling by invitation |
NCT05698550 -
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
|
Phase 3 | |
Not yet recruiting |
NCT03910582 -
Personalized FET in RIF Patients With Displaced Dating
|
N/A | |
Completed |
NCT05440019 -
Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
|
||
Completed |
NCT05130125 -
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
|